Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations-Reference-Cited by-同舟云学术

Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations

Published:2017-07-03 Issue:8 Volume:6 Page:1847-1860
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Tan Pui San¹,Bilger Marcel²,de Lima Lopes Gilberto³,Acharyya Sanchalika⁴,Haaland Benjamin⁵^ORCID

Affiliation:

1. Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford United Kingdom

2. Health Services & Systems Research; Duke-NUS Graduate Medical School; Singapore Singapore

3. Sylvester Comprehensive Cancer Center; University of Miami and the Miller School of Medicine; Miami Florida

4. Centre for Quantitative Medicine; Duke-NUS Graduate Medical School; Singapore Singapore

5. H. Milton Stewart School of Industrial and Systems Engineering; Georgia Institute of Technology; Atlanta Georgia

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1101/fullpdf

Reference40 articles.

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 2012 Int. Agency Res. Cancer http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

2. Lung cancer statistics 2014 http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-bycancer-type/lung-cancer/survival#heading-Zero

3. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data;Rossi;Lancet Oncol.,2014

4. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, hi;Tan;Eur. J. Cancer,2015

5. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea;Gerber;J. Clin. Oncol.,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients;Scientific Reports;2023-11-27

2. circ_0006528 promotes nonsmall cell lung cancer progression by sponging miR-892a and regulating NRAS expression;Anti-Cancer Drugs;2023-11-16

3. PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer;European Journal of Pharmacology;2023-10

4. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs;Thoracic Cancer;2023-09-22

5. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer;Journal of Clinical Oncology;2022-12-01